New drug shows promise in reducing COPD symptoms in smokers, clinical trials show
Summary
A new drug called tozorakimab, developed by AstraZeneca, has shown success in reducing symptoms of chronic obstructive pulmonary disease (COPD) in smokers during late-stage clinical trials. The drug targets a protein that causes inflammation and is being reviewed by the U.S. Food and Drug Administration (FDA) for faster approval.Key Facts
- COPD is a lung disease that worsens over time and is a leading cause of death in the U.S.
- Tozorakimab is the first biologic drug to reduce COPD symptoms by targeting a protein called interleukin-33.
- Patients received either tozorakimab injections every four weeks or a placebo in clinical trials.
- The drug reduced moderate to severe COPD flare-ups by about 29% to 34% in former and current smokers.
- Tozorakimab was generally well tolerated, with only mild side effects at the injection site.
- It is being developed for COPD and is also being studied for asthma and other lung diseases.
- The FDA has accepted tozorakimab for priority review, meaning they will speed up the approval process.
- Nearly 16 million adults in the U.S. have COPD, and smoking is the main cause of the disease.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
